Form 4: Elicio Therapeutics Director Acquires Stock Options

Allen Nissenson, a director of Elicio Therapeutics, acquired stock options for 7,900 shares of common stock on May 19, 2025.

Summary

• On May 19, 2025, Allen Nissenson, a director of Elicio Therapeutics, acquired stock options.
• The options grant the right to buy 7,900 shares of Elicio Therapeutics common stock at an exercise price of $5.84 per share.
• The stock options vest fully on the earlier of May 19, 2026, or the next annual meeting of the Company's stockholders after the grant date, contingent upon continued service to the Issuer.
• The options expire on May 19, 2035.
• Following the transaction, Nissenson directly owns 7,900 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment. This is a routine disclosure of stock option grants to a director, which is a common practice.

Positives

• The acquisition of stock options by a director signals confidence in the company's future prospects.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule is contingent on continued service to the Issuer.

Industry Context

This is a standard Form 4 filing, reflecting a common practice of granting stock options to directors as part of their compensation.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, incentivizing them to work towards increasing the company's value.

Key Dates

Keywords

stock options, director, Elicio Therapeutics, ELTX, Form 4, insider trading